ArticleJournal of orthopaedic case reports2025
Platelet-Rich Plasma Injections are Associated with Higher Resource Utilization and Surgical Escalation Compared with Corticosteroids in Lateral Elbow Tendinopathy.
Article in Journal of orthopaedic case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Epicondylitis (lateral and medial) is a common tendinopathy that impairs function and quality of life. Corticosteroid injections (CSI) provide rapid but often short-lived symptom relief, while platelet-rich plasma (PRP) is used as a biologic alternative aimed at tendon regeneration. Comparative effectiveness between PRP and CSI remains uncertain in real-world settings. Materials and Methods: We conducted a retrospective cohort study using de-identified electronic health records from the TriNetX Network (2010-2025). Adults ≥18 years with coded epicondylitis and subsequent PRP or CSI were included. Cohorts were 1:1 propensity-score matched on demographics and comorbidities (age, sex, race, type 2 diabetes, obesity, hypothyroidism, nicotine dependence). Outcomes were assessed over a period of 1 year after the index event and included repeat or new medication, opioid exposure, long-term opioid initiation, visits to the emergency department (ED), functional diagnoses (stiffness, weakness, mobility), physical therapy (PT) utilization, and surgical escalation. Hazard ratios (HRs) and risk ratios were estimated. Results: After matching, 1,064 PRP patients were compared with 1,064 CSI patients. PRP was associated with higher hazards of repeat or new medication (HR 1.33; 95% CI 1.18-1.50; RR 1.21), opioid exposure (HR 1.48; 95% CI 1.20-1.83; RR 1.43), PT utilization (HR 1.52; 95% CI 1.27-1.81; RR 1.41), joint stiffness (HR 1.64; 95% CI 1.04-2.59; RR 1.63), dependence on mobility aids (HR 3.63; 95% CI 1.80-7.31; RR 3.60), and surgical escalation (HR 2.57; 95% CI 1.19-5.56; RR 2.30). No significant differences were observed for ED visits, long-term opioid initiation, abnormal gait, muscle weakness, or contracture. Conclusion: In this large, multi-institutional real-world cohort, PRP was associated with higher short-term utilization and treatment failure risks compared with CSI. While randomized trials suggest mid-term benefits of PRP, our findings highlight an efficacy-effectiveness gap, likely reflecting heterogeneity in PRP protocols and patient selection. Clinicians should counsel patients about the potential for early symptom flare and higher downstream resource use when considering PRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.